Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.73 |
| ▸ | HTT | P42858 | 8/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358001 | 0.88 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL30379870 | 0.88 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL28473041 | 0.86 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL8686733 | 0.86 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL8690446 | 0.85 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL29377589 | 0.84 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL1418988 | 0.84 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL26552342 | 0.84 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL13621788 | 0.84 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A | |
| SCHEMBL28467279 | 0.83 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2HTTPTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081466-B2 | 2-aroylimidazole compounds for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20040186129-A1 | 2-Aroylimidazole compounds for treating cancer | KOYA KEIZO (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1427413-A2 | 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER | Synta Pharmaceuticals Corporation (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6743919-B2 | INCLUDING MULTI-DRUG RESISTANT CANCER CELLS FROM A NUMBER OF DIFFERENT TISSUE TYPES | SYNTA PHARMACEUTICALS CORP. | 2004-06-01 | — | — | US | disclosed |
| US-20030096836-A1 | 2-Aroylimidazole compounds for treating cancer | SBR PHARMACEUTICALS CORP. | 2003-05-22 | — | — | US | disclosed |
| WO-2003022274-A2 | 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096836-A1 | 2-Aroylimidazole compounds for treating cancer | NR4A1, NR0B2, NR0B1 | ALDH1A1 441/4885SMN1; SMN2 1877/4885HTT 4770/4885 |
| US-20040186129-A1 | 2-Aroylimidazole compounds for treating cancer | TOP2B, HDAC11, CYP4B1 | ALDH1A1 215/4885SMN1; SMN2 2405/4885HTT 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.